TR199700625T1 - Osteoporoz (kemik erimesi) tedavisinde yararli olan indol türevleri. - Google Patents

Osteoporoz (kemik erimesi) tedavisinde yararli olan indol türevleri.

Info

Publication number
TR199700625T1
TR199700625T1 TR97/00625T TR9700625T TR199700625T1 TR 199700625 T1 TR199700625 T1 TR 199700625T1 TR 97/00625 T TR97/00625 T TR 97/00625T TR 9700625 T TR9700625 T TR 9700625T TR 199700625 T1 TR199700625 T1 TR 199700625T1
Authority
TR
Turkey
Prior art keywords
optionally substituted
group
alkyl
aryl
formula
Prior art date
Application number
TR97/00625T
Other languages
English (en)
Inventor
Farina Carlo
Gagliardi Stefania
Parini Carlo
Pinza Mario
Marguerite Marie Gerard Nadler Guy
Jean-Marie Morvan Marcel
Original Assignee
Smithkline Beecham S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI950030A external-priority patent/IT1272878B/it
Priority claimed from ITMI951687 external-priority patent/IT1307328B1/it
Application filed by Smithkline Beecham S.P.A. filed Critical Smithkline Beecham S.P.A.
Publication of TR199700625T1 publication Critical patent/TR199700625T1/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Ra'nin hidrojen alkil veya tercihe göre ikame edilmis aril olan bir R5 grubunu, Rb'nin ise asagidaki formülün a() bir bölümünü temsil ettigi: (formül) bu formül (a)'da, X, alkil grubunun istege göre ikame edebildigi, bir hidroksi veya bir alkoksi grubunu, veya R5 ve Rt'nin ayri ayri bagimsiz olarak hidrojeni alkili, ikameli alkili, tercihe göre ikameli alkenili, tercihe göre ikameli arili, tercihe göre ikameli arilalkili, tercihe göre ikameli bir heterosiklik grubu veya tercihe göre ikameli bir heterosiklialkil grubunu temsil ettigi veya R5 ile Rt'nin birlikte bir heterosiklik grup olusturdugu bir NR5Rt grubunu; R1 bir alkil veya ikameli/ikamesiz aril grubunu; ve R2,R3 ve R4'ün her biri bagimsizca hidrojen, alkil, aril veya ikameli arili temsil eder; veya Ra'nin yukaridaki formül (a)'nin bir kismini, ve Rb yukarida tanimlanan R5'i temsil ettigi; R6 ve R7'nin ayri ayri hidrojen, hidroksi, amino, alkoksi, tercihe göre ikameli benziloksi, lakilamin, dialkiamino, halo, ...(devami var).
TR97/00625T 1995-01-10 1996-01-08 Osteoporoz (kemik erimesi) tedavisinde yararli olan indol türevleri. TR199700625T1 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI950030A IT1272878B (it) 1995-01-10 1995-01-10 Composti indolici
ITMI951687 IT1307328B1 (it) 1995-08-01 1995-08-01 Composti indolici

Publications (1)

Publication Number Publication Date
TR199700625T1 true TR199700625T1 (tr) 1998-02-21

Family

ID=26331230

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/00625T TR199700625T1 (tr) 1995-01-10 1996-01-08 Osteoporoz (kemik erimesi) tedavisinde yararli olan indol türevleri.

Country Status (19)

Country Link
US (1) US5981525A (tr)
EP (1) EP0802902A1 (tr)
JP (1) JPH10512251A (tr)
KR (1) KR19980701330A (tr)
AP (1) AP648A (tr)
AU (1) AU4536096A (tr)
BG (1) BG101769A (tr)
BR (1) BR9606743A (tr)
CA (1) CA2209936A1 (tr)
CZ (1) CZ217697A3 (tr)
EA (1) EA199700098A1 (tr)
FI (1) FI972919A (tr)
HU (1) HUP9901096A3 (tr)
NO (1) NO973178L (tr)
OA (1) OA10611A (tr)
PL (1) PL321263A1 (tr)
SK (1) SK93297A3 (tr)
TR (1) TR199700625T1 (tr)
WO (1) WO1996021644A1 (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
GB9614366D0 (en) * 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
PL330994A1 (en) * 1996-07-09 1999-06-21 Smithkline Beecham Spa Indolic derivatives for use in treating osteoporosis
GB9614347D0 (en) * 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
GB9703109D0 (en) * 1997-02-14 1997-04-02 Smith & Nephew Compositions
AU6229698A (en) * 1997-02-21 1998-09-09 Takeda Chemical Industries Ltd. Fused ring compounds, process for producing the same and use thereof
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1999033822A1 (en) * 1997-12-24 1999-07-08 Smithkline Beecham Laboratoires Pharmaceutiques Indole derivatives useful a.o. for the treatment of osteoporosis
US6506758B2 (en) 1997-12-24 2003-01-14 Smithkline Beecham Laboratoires Pharmceutiques Indole derivatives useful A.O. for the treatment of osteoporosis
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
WO1999036422A1 (en) 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
GB9914371D0 (en) * 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) * 1999-11-18 1999-11-18 Astra Ab New use
AU2002254616B2 (en) * 2001-04-11 2007-09-06 Idenix (Cayman) Limited Phenylindoles for the treatment of HIV
JP2005510482A (ja) * 2001-10-16 2005-04-21 アストラゼネカ・アクチエボラーグ 線維筋痛症候群の治療方法
WO2004014364A1 (en) * 2002-08-07 2004-02-19 Idenix (Cayman) Limited Substituted phenylindoles for the treatment of hiv
ITMI20040875A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici utili per il trattamento della resistenza agli agenti antitumorali
DE602005023360D1 (de) 2004-09-17 2010-10-14 Idenix Pharmaceuticals Inc Phosphoindole als HIV-Inhibitoren
EP1861394A1 (en) * 2005-03-03 2007-12-05 H.Lundbeck A/S Substituted pyridine derivatives
NZ575831A (en) * 2006-09-29 2011-12-22 Idenix Pharmaceuticals Inc Enantiomerically pure phosphoindoles as hiv inhibitors
LU91725B1 (en) 2010-09-02 2012-03-05 Ct De Rech Public De La Sante Novel uses of V-ATPASE inhibitors
US9115128B2 (en) * 2013-06-06 2015-08-25 Anthem Biosciences Pvt. Ltd. Compounds of 3-(5-substituted Oxy-2, 4-dinitrophenyl)-2-oxo-propionic acid ester, synthesis and applications thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449496B1 (en) * 1990-03-20 1994-07-20 Sharp Kabushiki Kaisha Method for mounting a semiconductor device
CA2038925A1 (en) * 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification

Also Published As

Publication number Publication date
MX9705243A (es) 1997-10-31
AP9701029A0 (en) 1997-07-31
FI972919A (fi) 1997-09-09
NO973178L (no) 1997-09-09
US5981525A (en) 1999-11-09
BG101769A (en) 1998-04-30
AU4536096A (en) 1996-07-31
NO973178D0 (no) 1997-07-09
EA199700098A1 (ru) 1997-12-30
JPH10512251A (ja) 1998-11-24
OA10611A (en) 2002-09-03
CA2209936A1 (en) 1996-07-18
HUP9901096A3 (en) 2000-12-28
HUP9901096A2 (hu) 1999-07-28
CZ217697A3 (cs) 1998-03-18
KR19980701330A (ko) 1998-05-15
EP0802902A1 (en) 1997-10-29
SK93297A3 (en) 1998-02-04
BR9606743A (pt) 1997-12-30
AP648A (en) 1998-05-25
WO1996021644A1 (en) 1996-07-18
PL321263A1 (en) 1997-11-24
FI972919A0 (fi) 1997-07-09

Similar Documents

Publication Publication Date Title
TR199700625T1 (tr) Osteoporoz (kemik erimesi) tedavisinde yararli olan indol türevleri.
NO921287L (no) Nytt bindeledd for bioaktive midler
TR199901653T2 (tr) Fitalazinonlar.
DK0682663T3 (da) 4-Hydroxybenzopyran-2-oner og 4-hydroxycycloalkyl[b]pyran-2-oner, der er nyttige til behandling af retrovirale infektioner
NZ507735A (en) Indole derivatives useful for treating malignant and other diseases caused by pathological cell proliferation
TR199902357T2 (tr) Yeni bilesimler.
TR200002482T2 (tr) 6,9-Diikameli 2-(Trans-(4-Aminosiklohekzil) Amino)Pürinler
DE69818042D1 (de) Flüssige benzisochinoline derivate
ES2012646A6 (es) Un procedimiento para la preparacion de derivados de piridazinona.
PT918776E (pt) Sintese total de acilfulvenos antitumorais
PT91575A (pt) Procede de preparation de benzylamines disubstituees utiles comme medicaments
IT1315267B1 (it) Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita&#39;antitumorale
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
TR200000227T2 (tr) Piperazin içeren reaktif boyalar.
ATE262509T1 (de) Indolinderivate als lichtschutzmittel
TR200001992T2 (tr) Osteoporoz tedavisinde de yararlı olan indol türevleri.
MX9701949A (es) Derivados de distamicina substituidos con bis-(2-haloetil) aminofenilo como agentes antitumorales y antivirales.
AU2713897A (en) Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
TR199902873T2 (tr) Miyozun modülasyonu için 17 -aliloksi(tiyo)alkil-androstan türevleri.
ES2152563T3 (es) Procedimiento para preparar derivados de dihidroxipirimidina.
TR200201689T2 (tr) Yeni indol türevleri
TR199800110T1 (tr) Azotiofenler.
TR200100133T2 (tr) FKBP İnhibitörleri
IL123080A0 (en) Carbamoylcarboxamides their preparation and use
TR200002485T2 (tr) N-Sülfonil ve N-Sülfinil Fenilglisinamid